Context Therapeutics Inc.
CNTX•NASDAQ•Healthcare•Biotechnology

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMartin Lehr
Founded2015
IPO DateOctober 20, 2021
Employees12
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.contexttherapeutics.com
Phone267 225 7416
Address
2001 Market Street, Suite 3915 Philadelphia, Pennsylvania 19103 United States

Corporate Identifiers

CIK0001842952
CUSIP21077P108
ISINUS21077P1084
EIN86-3738787
SIC2834

Leadership Team & Key Executives

Martin A. Lehr
Co-Founder, President, Chief Executive Officer and Director
Jennifer Minai-Azary
Chief Financial Officer and Treasurer
Alex C. Levit Esq., J.D.
Chief Legal Officer and Corporate Secretary
Christopher Beck M.B.A.
Senior Vice President of Operations
Jeffrey Liebman
Associate Director of Accounting
Jennifer Dashnau M.B.A., Ph.D.
Senior Vice President of Technical Operations
Dr. Karen Chagin M.D.
Chief Medical Officer